ESMO 2022 Highlights

CME

Key Studies in Breast, Gynecologic, Renal Cell, Urothelial, Lung, Hepatobiliary, and Skin Cancers: CCO Independent Conference Highlights of the 2022 ESMO Congress
Credits Available

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: November 14, 2022

Expiration: November 13, 2023

Pretest

Progress
1 2
Course Completed
1.
Which of the following findings was reported from the TROPiCS-02 trial for sacituzumab govitecan when compared with physician's choice of chemotherapy in patients with hormone receptor–positive/HER2-negative breast cancer?